Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Loss in Obese Subjects

NCT06633783 is registered in ClinicalTrials.gov with Hangzhou Jiuyuan Gene Engineering Co. Ltd., as lead sponsor.

NCT NCT06633783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06633783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Loss in Obese Subjects
Lead sponsor
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 30, 2024
Completion date
October 30, 2026
Enrollment
370 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

obesity